Skip to main content

Advertisement

SpringerLink
Log in

Dry powder inhaler for pulmonary drug delivery: human respiratory system, approved products and therapeutic equivalence guideline

  • Review
  • Published:
Journal of Pharmaceutical Investigation Aims and scope Submit manuscript

Abstract

Pulmonary drug delivery is the promising delivery route to treat not only respiratory diseases but also systemic diseases and has proven as a potential delivery route for complex drugs that cannot be delivered orally. Development of dry powder inhalation systems targets the delivery of fine drug particles to the deep lung surface by a combination of particle deposition and clearance in human respiratory tract. Various dry powder inhalers (DPIs) with their advanced technologies have been proposed and marketed to treat pulmonary diseases such as asthma, chronic obstructive pulmonary diseases, cystic fibrosis and furthermore, systemic diseases such as diabetes and schizophrenia. Bioequivalent therapeutic effects can be derived from generic products that provide additional benefits to the patients and the health care system. Currently, European Medicines Agency (EMA) have established the bioequivalent methods to develop and approve the inhaled products. This review covers the anatomical and physiological characteristics of human respiratory tract to understand the mechanism of drug deposition and clearance. Also, therapeutic areas for both local and systemic treatment, DPI products and their advanced technologies are presented. Finally, European Medicines Agency (EMA) guidelines for inhaled products are presented to demonstrate the therapeutic bioequivalence between generic and reference products.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Atkins PJ (2005) Dry powder inhalers: an overview. Respir Care 50(10):1304–1312

    PubMed  Google Scholar 

  • Beasley R, Semprini A, Mitchell EA (2015) Risk factors for asthma: is prevention possible? Lancet 386(9998):1075–1085

    Article  PubMed  Google Scholar 

  • Beck-Broichsitter M, Merkel OM, Kissel T (2012) Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J Control Release 161(2):214–224

    Article  CAS  PubMed  Google Scholar 

  • Bell KA (1974) Aerosol deposition in models of a human lung bifurcation. Xerox University Microfilms, Ann Arbor

    Google Scholar 

  • Boe J, Dennis J, O’driscoll B, Bauer T, Carone M, Dautzenberg B, Diot P, Heslop K, Lannefors L (2001) European respiratory society guidelines on the use of nebulizers. Eur Respir J 18(1):228–242

    Article  CAS  PubMed  Google Scholar 

  • Boucher RC (2002). An overview of the pathogenesis of cystic fibrosis lung disease, Elsevier, Amsterdam

    Book  Google Scholar 

  • Boucher RC (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 23(1):146–158

    Article  CAS  PubMed  Google Scholar 

  • Broeders M, Molema J, Vermue N, Folgering H. T. M. (2001) Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur Respir J 18(5):780–783

    Article  CAS  PubMed  Google Scholar 

  • Buttini F, Brambilla G, Copelli D, Sisti V, Balducci AG, Bettini R, Pasquali I (2016) Effect of flow rate on in vitro aerodynamic performance of NEXThaler® in comparison with Diskus® and Turbohaler® Dry Powder Inhalers. J Aerosol Med Pulm Drug Deliv 29(2):167–178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carvalho TC, Peters JI, Williams RO (2011) Influence of particle size on regional lung deposition–what evidence is there? Int J Pharm 406(1):1–10

    Article  CAS  PubMed  Google Scholar 

  • Ceglia L, Lau J, Pittas AG (2006) Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 145(9):665–675

    Article  PubMed  Google Scholar 

  • Chan JGY, Chan H-K, Prestidge CA, Denman JA, Young PM, Traini D (2013) A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur J Pharm Biopharm 83(2):285–292

    Article  CAS  PubMed  Google Scholar 

  • Chan JGY, Wong J, Zhou QT, Leung SSY, Chan H-K (2014) Advances in device and formulation technologies for pulmonary drug delivery. AAPS Pharm Sci Tech 15(4):882–897

    Article  CAS  Google Scholar 

  • Chapman KR (2002) Seretide for obstructive lung disease. Expert Opin Pharmacother 3(3):341–350

    Article  CAS  PubMed  Google Scholar 

  • Cheng YS (2014) Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech 15(3):630–640

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Clarke SW (2015) Anatomy and physiology of the human lung: aspects relevant to aerosols. Aerosols and the lung: clinical and experimental aspects 1

  • Cooper S, Oborne J, Harrison T, Tattersfield A (2009) Effect of mouth taping at night on asthma control–A randomised single-blind crossover study. Respir Med 103(6):813–819

    Article  PubMed  Google Scholar 

  • Corradi M, Chrystyn H, Cosio BG, Pirozynski M, Loukides S, Louis R, Spinola M, Usmani OS (2014) NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv 11(9):1497–1506

    Article  CAS  PubMed  Google Scholar 

  • Cotes JE, Chinn DJ, Miller MR (2009) Lung function: physiology, measurement and application in medicine. Wiley, Hoboken

    Google Scholar 

  • Dalby R, Spallek M, Voshaar T (2004) A review of the development of Respimat® Soft Mist™ Inhaler. Int J Pharm 283(1):1–9

    Article  CAS  PubMed  Google Scholar 

  • Daley-Yates PT, Parkins DA (2011) Establishing bioequivalence for inhaled drugs; weighing the evidence. Expert Opin Drug Deliv 8(10):1297–1308

    Article  CAS  PubMed  Google Scholar 

  • Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E (2013) Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother 57(6):2613–2619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dinh KV, Myers DJ, Noymer PD, Cassella JV (2010) In vitro aerosol deposition in the oropharyngeal region for Staccato® loxapine. J Aerosol Med Pulm Drug Deliv 23(4):253–260

    Article  CAS  PubMed  Google Scholar 

  • Dunne S, Shannon B, Dunne C, Cullen W (2013) A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol 14(1):1

    Article  PubMed  PubMed Central  Google Scholar 

  • Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A (2003) Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167(3):418–424

    Article  PubMed  Google Scholar 

  • Fiegel J, Garcia-Contreras L, Thomas M, VerBerkmoes J, Elbert K, Hickey A, Edwards D (2008) Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res 25(4):805–811

    Article  CAS  PubMed  Google Scholar 

  • García-Arieta A (2014) A European perspective on orally inhaled products: In vitro requirements for a biowaiver. J Aerosol Med Pulm Drug Deliv 27(6):419–429

    Article  PubMed  Google Scholar 

  • Geller DE, Weers J, Heuerding S (2011) Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. J Aerosol Med Pulm Drug Deliv 24(4):175–182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • George AM, Jones PM, Middleton PG (2009) Cystic fibrosis infections: treatment strategies and prospects. FEMS Microbiol Lett 300(2):153–164

    Article  CAS  PubMed  Google Scholar 

  • Glover W, Chan H-K, Eberl S, Daviskas E, Verschuer J (2008) Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int J Pharm 349(1):314–322

    Article  CAS  PubMed  Google Scholar 

  • Grant AC, Walker R, Hamilton M, Garrill K (2015) The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug deliv 28(6):474–485

    Article  PubMed  PubMed Central  Google Scholar 

  • Hamman JH, Enslin GM, Kotzé AF (2005) Oral delivery of peptide drugs. BioDrugs 19(3):165–177

    Article  CAS  PubMed  Google Scholar 

  • Haq IJ, Gray MA, Garnett JP, Ward C, Brodlie M (2015) Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. Thorax. doi:10.1136/thoraxjnl-2015-207588

    Article  PubMed  Google Scholar 

  • Hastedt JE, Bäckman P, Clark AR, Doub W, Hickey A, Hochhaus G, Kuehl PJ, Lehr C-M, Mauser P, McConville J (2016) Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD. AAPS Open 2(1):1

    Article  Google Scholar 

  • Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W (1986) Deposition of particles in the human respiratory tract in the size range 0.005–15 μm. J Aerosol Sci 17(5):811–825

    Article  Google Scholar 

  • Høiby N, Ciofu O, Bjarnsholt T (2010) Pseudomonas aeruginosa biofilms in cystic fibrosis. Future microbiology 5(11):1663–1674

    Article  PubMed  Google Scholar 

  • Island OA (1916) New recertification deadlines take effect for active PTCB certified pharmacy technicians. Omni 7:17/16

    Google Scholar 

  • Janssen WJ, Stefanski AL, Bochner BS, Evans CM (2016) Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions. Eur Respir J ERJ doi:10.1183/13993003.00120-2015

    Article  Google Scholar 

  • Klonoff DC (2014) Afrezza inhaled insulin: the fastest-acting FDA-approved insulin on the market has favorable properties. SAGE Publications Sage CA, Los Angeles

    Book  Google Scholar 

  • Knechel NA (2009) Tuberculosis: pathophysiology, clinical features, and diagnosis. Crit Care Nurse 29(2):34–43

    Article  PubMed  Google Scholar 

  • Koch C, Hoiby N (1993) Pathogenesis of cystic fibrosis. Lancet 341(8852):1065–1069

    Article  CAS  PubMed  Google Scholar 

  • Kuna P, Kuprys I (2002) Symbicort Turbuhaler: a new concept in asthma management. Int J Clin Pract 56(10):797–803

    CAS  PubMed  Google Scholar 

  • Lavorini F, Ninane V, Haughney J, Bjermer L, Molimard M, Dekhuijzen RP (2013). Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Taylor & Francis, Abingdon

  • Lavorini F, Fontana GA, Usmani OS (2014) New inhaler devices-the good, the bad and the ugly. Respiration 88(1):3–15

    Article  PubMed  Google Scholar 

  • Lee RJ, Chen B, Doghramji L, Adappa ND, Palmer JN, Kennedy DW, Cohen NA (2013) Vasoactive intestinal peptide regulates sinonasal mucociliary clearance and synergizes with histamine in stimulating sinonasal fluid secretion. FASEB J 27(12):5094–5103

    Article  CAS  PubMed  Google Scholar 

  • Lee JO, Youn YS, Lee D-K, Cha K-H, Lee ES (2015) Development of poly (lactic-co-glycolic acid) microparticles with pH-sensitive drug release behaviors. J Pharm Invest 45(2):151–156

    Article  CAS  Google Scholar 

  • Leung AN (1999) Pulmonary tuberculosis: the essentials. Radiology 210(2):307–322

    Article  CAS  PubMed  Google Scholar 

  • Lim JY, Kim NA, Lim DG, Kim KH, Choi DH, Jeong SH (2016) Process cycle development of freeze drying for therapeutic proteins with stability evaluation. J Pharm Invest 46(6):519–536

    Article  CAS  Google Scholar 

  • Lumb AB (2016) Nunn’s applied respiratory physiology. Elsevier Health Sciences, Amsterdam

    Google Scholar 

  • Malcolmson RJ, Embleton JK (1998) Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today 1(9):394–398

    Article  CAS  Google Scholar 

  • Mansour HM, Park C-W, Hayes D Jr (2013) Nanoparticle lung delivery and inhalation aerosols for targeted pulmonary nanomedicine. CRC Press, Taylor & Francis Group, Boca Raton

    Book  Google Scholar 

  • Miller-Larsson A, Selroos O (2006) Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting β2-agonists. Curr Pharm Des 12(25):3261–3279

    Article  CAS  PubMed  Google Scholar 

  • Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B (2013) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187(7):680–689

    Article  PubMed  Google Scholar 

  • Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, Weers JG (2003) Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest J 124(1):360–366

    Article  CAS  Google Scholar 

  • Nolan SJ, Thornton J, Murray CS, Dwyer T (2016) Inhaled mannitol (Bronchitol) for cystic fibrosis. Paediatr Respir Rev 18:52–54

    PubMed  Google Scholar 

  • Onoue S, Hashimoto N, Yamada S (2008) Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins. Expert Opin Ther Pat 18(4):429–442

    Article  CAS  Google Scholar 

  • Patton JS (1996) Mechanisms of macromolecule absorption by the lungs. Adv Drug Delivery Rev 19 1:3–36

    Article  Google Scholar 

  • Pfützner A, Forst T (2005) Pulmonary insulin delivery by means of the Technosphere™ drug carrier mechanism. Expert Opin Drug Deliv 2(6):1097–1106

    Article  PubMed  Google Scholar 

  • Pfützner A, Mann AE, Steiner SS (2002) Technosphere™/Insulin—a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 4(5):589–594

    Article  PubMed  Google Scholar 

  • Pittas AG, Westcott GP, Balk EM (2015) Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 3(11):886–894

    Article  CAS  PubMed  Google Scholar 

  • Postma DS, Rabe KF (2015) The asthma–COPD overlap syndrome. N Engl J Med 373(13):1241–1249

    Article  CAS  PubMed  Google Scholar 

  • Pressman JJ, Kelemen G (1955) Physiology of the larynx. Physiol Rev 35(3):506–554

    Article  CAS  PubMed  Google Scholar 

  • Ratjen FA (2009) Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 54(5):595–605

    Article  PubMed  Google Scholar 

  • Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson S, Bye P (1999) The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 14(3):678–685

    Article  CAS  PubMed  Google Scholar 

  • Rommens JM, Iannuzzi MC, Kerem B.-s., Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245(4922):1059–1065

    Article  CAS  PubMed  Google Scholar 

  • Salvi S (2014) Tobacco smoking and environmental risk factors for chronic obstructive pulmonary disease. Clin Chest Med 35(1):17–27

    Article  PubMed  Google Scholar 

  • Sapakal V, Govindasamy J (2015) Bioequivalence of orally inhaled drug products: focus on current regulatory perspectives. Ind Med Gaz 4:151–161

    Google Scholar 

  • Schuster A, Haliburn C, Döring G, Goldman MH (2012) Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. doi:10.1136/thoraxjnl-2012-202059

    Article  PubMed  PubMed Central  Google Scholar 

  • Sciurba FC (2004) Physiologic similarities and differences between COPD and asthma. CHEST J 126(2_suppl_1):117S–124S

    Article  Google Scholar 

  • Steiner S, Pfützner A, Wilson B, Harzer O, Heinemann L, Rave K (2002) TechnosphereTM/Insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 110(01):17–21

    Article  CAS  PubMed  Google Scholar 

  • Sulis G, Roggi A, Matteelli A, Raviglione MC (2014) Tuberculosis: epidemiology and control. Mediterr. J Hematol. Infect. Dis 6(1):2014070

    Article  Google Scholar 

  • Sung JC, Pulliam BL, Edwards DA (2007) Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25(12):563–570

    Article  CAS  PubMed  Google Scholar 

  • Svedsater H, Dale P, Garrill K, Walker R, Woepse MW (2013) Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med 13 1:72

    Article  Google Scholar 

  • Tan W, Sin D, Bourbeau J, Hernandez P, Chapman K, Cowie R, FitzGerald J, Marciniuk D, Maltais F, Buist AS (2015) Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. Thorax 70(9):822–829

    Article  CAS  PubMed  Google Scholar 

  • Taulbee DB, Yu C (1975) A theory of aerosol deposition in the human respiratory tract. J Appl Physiol 38(1):77–85

    Article  CAS  PubMed  Google Scholar 

  • Tena AF, Clarà PC (2012) Deposition of inhaled particles in the lungs. Archivos de Bronconeumología (English Edition) 48(7):240–246

    Google Scholar 

  • Use C. f. M. P. f. H (2009) Guideline on the requirements for clinical documentation for orally inhaled products (oip) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulm. European Medicines Agency. Available online at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin e/2009/09/WC500003504.pdfv

  • Valdes J, Shipley T, Rey JA (2014) Loxapine inhalation powder (adasuve): a new and innovative formulation of an antipsychotic treatment for agitation. Pharm Therapeutics 39(9):621

    Google Scholar 

  • VanDevanter DR, Geller DE (2011) Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review. Med Devices 4:179–188

    Article  CAS  Google Scholar 

  • Verma RK, Ibrahim M, Garcia-Contreras L (2015) Lung anatomy and physiology and their implications for pulmonary drug delivery. Pulmonary drug delivery: advances and challenges, pp 1–18

  • Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187(4):347–365

    Article  CAS  PubMed  Google Scholar 

  • Wania RLS. (2013) Tuberculosis 2: Pathophysiology and microbiology of pulmonary tuberculosis. South Sudan Med J 6(1):10–12

    Google Scholar 

  • Weibel ER (2001) Why measure lung structure? Am J Respir Crit Care Med 163(2):314–315

    Article  CAS  PubMed  Google Scholar 

  • Wright P (2016) 10 Inhalation dosage forms. Pharmaceutical preformulation and formulation: a practical guide from candidate drug selection to commercial dosage form 348

  • Yun Kirby S, Zhu C-Q, Kerwin EM, Stanford RH, Georges G (2016) A preference study of two placebo dry powder inhalers in adults with COPD: Ellipta® dry powder inhaler (DPI) versus DISKUS® DPI. COPD 13(2):167–175

    Article  PubMed  Google Scholar 

  • Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, Retsch-Bogart G, Saiman L, Accurso FJ (2010) Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros 9(1):1–16

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, Chungbuk National University, 194-21, Osongsangmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungcheongbuk-do, 28644, Republic of Korea

    Hong-Goo Lee & Chung-Woong Park

  2. Department of Pharmaceutical Engineering, Cheongju University, Cheongju, 28530, Republic of Korea

    Dong-Wook Kim

Authors
  1. Hong-Goo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong-Wook Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chung-Woong Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chung-Woong Park.

Ethics declarations

Conflict of interest

All authors (H. Lee, D. Kim, C. Park) declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human or animal subjects performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, HG., Kim, DW. & Park, CW. Dry powder inhaler for pulmonary drug delivery: human respiratory system, approved products and therapeutic equivalence guideline. J. Pharm. Investig. 48, 603–616 (2018). https://doi.org/10.1007/s40005-017-0359-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40005-017-0359-z

Keywords

Search

Navigation